Pipeline Therapeutics Signs Licensing Agreement with Janssen for Investigational Neurotherapeutic, PIPE-307
By Shweta Gupta
Pharma Deals Review: Vol 2023 Issue 5 (Table of Contents)
Published: 11 May-2023
DOI: 10.3833/pdr.v2023.i5.2782 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to bolster its neuroscience portfolio, Janssen has entered into a global license and development agreement with Pipeline Therapeutics for the investigational compound, PIPE-307, to treat nervous system disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS